ÀÚµ¿·Î±×¾Æ¿ô¾È³»
ÀÚµ¿ ·Î±×¾Æ¿ô ³²Àº ½Ã°£ : 30ÃÊ
°í°´´ÔÀÇ ¾ÈÀüÇÑ Á¤º¸º¸¾ÈÀ» À§ÇØ ·Î±×ÀÎ ÈÄ ¾à10ºÐµ¿¾È ¼ºñ½º ÀÌ¿ëÀÌ ¾ø¾î ÀÚµ¿ ·Î±×¾Æ¿ô µË´Ï´Ù. ·Î±×ÀÎ ½Ã°£À» ¿¬ÀåÇϽðڽÀ´Ï±î?
ÀÚµ¿·Î±×¾Æ¿ô¾È³»
°í°´´ÔÀÇ ¾ÈÀüÇÑ Á¤º¸º¸¾ÈÀ» À§ÇØ ·Î±×ÀÎ ÈÄ ¾à10ºÐµ¿¾È ¼ºñ½º ÀÌ¿ëÀÌ ¾ø¾î ÀÚµ¿ ·Î±×¾Æ¿ô µÇ¾ú½À´Ï´Ù.
½Ã°£ | ³»¿ë |
---|---|
09:00 | µî·Ï |
09:50 - 10:00 | °³È¸½Ä |
Session 1 | Chairs: Agneta Siegbahn(¿ó»ì¶ó´ë) & È«°æ¼ø(ÇѸ²ÀÇ´ë) |
10:00 - 10:30 | Micro RNA, extracellular vesicles and novel biomarker methods in cardiovascular disease |
10:30 - 10:50 | Unmet needs in the management of acute myocardial infarction: from pharmacodynamic perspectives |
10:50 - 11:20 | Clinical utility of biomarkers in cardiovascular disease |
11:20 - 11:40 | Clinical meaning of vasa vasorum: from early atherosclerosis to the vulnerable plaque |
11:40 - 12:00 | Discussion |
12:00 - 13:20 | Lunch |
Session 2 | Chairs: Jonas Oldgren(¿ó»ì¶ó´ë) & Á¶¸íÂù(ÃæºÏÀÇ´ë) |
13:20 - 13:50 | New concept for pragmatic clinical trials in cardiovascular disease |
13:50 - 14:10 | Acute heart failure in Korea: Focused on temporal trends |
14:10 - 14:30 | Hypertension in Korea: Focused on age and subclinical target organ damages |
14:30 - 14:50 | Discussion |
14:50 - 15:10 | Coffee Break |
- | Chairs: ÀüÀº¼®(¼º±Õ°üÀÇ´ë) & À̳²È£(ÇѸ²ÀÇ´ë) |
15:10 - 15:40 | Real world evidence confirming results from clinical trials |
15:40 - 16:00 | Acute myocardial infarction in Korea: Focused on current treatment and outcomes |
16:00 - 16:20 | Peripartum cardiomyopathy in Korea: Focused on prevalence and risk factors |
16:20 - 16:40 | Discussion |
16:40 - 17:00 | Æóȸ½Ä |